Serum-free Cell Culture Media for Antibody Production

Production of Therapeutic Antibodies in Animal-Free, Serum-Free Cell Culture

Common cell lines used to produce antibodies for research and downstream clinical applications include hybridoma, Chinese hamster ovary (CHO) cells, HEK293t, and others. Like all cultured mammalian cells, these cell lines must be maintained in media supplemented with critical extracellular proteins like transferrin for iron management, insulin for nutrient uptake, and albumin to support optimal cellular health and growth.

Cell cultures used for biomanufacturing of antibodies destined for therapeutic applications must be scalable and meet rigorous cGMP and regulatory standards for manufacturing quality, safety, performance, consistency, and efficiency. The undefined and variable composition of traditional cell-culture supplements like bovine serum albumin (BSA) and fetal bovine serum (FBS) introduce potential concerns about safety, supply, scalability, and compliance.

InVitria offers fully recombinant human serum protein supplements and chemically defined media for regulatory-friendly, serum-reduced or serum-free culture of hybridomas, CHO, HEK293t and other immortalized cell lines in traditional and batch culture. All products are manufactured biosynthetically in the US, using recombinant DNA technology in an animal-free host, in an ISO 9001:2015 certified facility. These products are suitable for RUO and cGMP uses and enable the reduction or elimination of serum, serum-purified proteins, and serum-derived contaminants from cell culture media at any scale.

InVitria’s products applicable to antibody manufacturing:

Reduce or eliminate the introduction of animal-derived viral RNA, DNA, prion proteins, and cytokines, prion proteins, undefined antigenic molecules, and animal-derived cytokines and hormones.
Provide improved consistency, scalability in cell growth, and more dependable manufacturing yield, product validation, and clinical safety of downstream clinical products.
Eliminate concerns about the fluctuating global supply chain and limitations on availability of bovine serum.

Animal-Free, Serum-Free Cell Culture Components and Supplements:

Cellastim S recombinant human albumin to replace BSA or purified human albumin in cell culture.
Optiferrin recombinant human transferrin for managing iron in serum-free or serum-reduced culture applications.
Insulin-transferrin supplements provide supplemental rh-insulin, rh-transferrin, and selenium, with or without ethanolamine and rh-albumin for serum-free or serum-reduced culture applications.
Exbumin excipient-grade recombinant human albumin to stabilize therapeutic antibodies throughout production and in final formulation.

These products are recommended for use with most cultured eukaryotic cell types, including:

Hybridoma cells
Chinese hamster ovary
HEK293t
Other immortalized and primary cell lines

At a Glance: InVitria Product for Antibody Production:

Antibody Production

Name	Function	Recombinant	Human sequence	Animal Free	Blood Free	IgG Free	Available grades
Cellastim S	Animal-free, serum-free recombinant human albumin to replace BSA and FBS in serum-free or serum-reduced cell culture.	✅	✅	✅	✅	✅	cGMP
Optiferrin	Animal-free, serum-free recombinant human transferrin for iron nutrition and management in serum-free or serum-reduced culture applications.	✅	✅	✅	✅	✅	cGMP
ITS, ITSE, ITSE+A Insulin-Transferrin Supplements	Provides supplemental rh-insulin rh-transferrin, and selenium, with or without ethanolamine and rh-albumin for serum-free or serum-reduced culture applications.	✅	✅	✅	✅	✅	cGMP
Exbumin	Excipient-grade, animal-free, serum-free recombinant human albumin to improve antibody stability throughout the production process. Exbumin is approved for use as an excipient in injectable therapeutics.	✅	✅	✅	✅	✅	cGMP

Related Resources

Resource Type	Title	Cell Lines	Relevance
Application Note	High-Resolution Analytical Characterization of Optibumin®: Structural Homogeneity and Functional Consistency Compared to Plasma-Derived HAS	—	Lot-to-lot consistency and reduced aggregates relevant to mAb formulation work.
Application Note	Safe, Consistent Iron Delivery in Serum-Free Systems with Optiferrin® Recombinant Transferrin	Hybridoma	Optiferrin matches plasma transferrin in hybridoma proliferation — supports serum-free mAb production workflows.
Application Note	Reducing Serum-Associated Contaminants from Growth Media in Primary Cell Culture	—	ITSE+A serum replacement for primary cell culture in antibody production workflows.
White Paper	Emergence of Blood-Free Recombinant Human Albumin	—	Foundational rHSA white paper covering antibody production applications.
White Paper	Optiferrin – Recombinant Transferrin an Iron Transport Protein in Cell Culture Media	—	Foundational Optiferrin overview: structure, function, and use in defined cell culture media.
Poster	Cellastim S – Optimizing Antibody Production in Animal-Free Media with the Supplementation of Recombinant Human Albumin	CHO, Hybridoma	Cellastim S delivers 50% IVCN increase and 92-140% titer improvement in CHO mAb production across multiple media.
Blog	Beyond Synthetic Surfactants: The Case for Recombinant Human Serum Albumin (rHSA) as an Ideal Alternative to Poloxamer 188	CHO, T Lymphocyte	Comparative data showing 50% IVCC and 92-140% titer increases over P188 in CHO mAb production.
Blog	Replacing the “Necessary Evil”: Recombinant Human Serum Albumin as a Chemically Stable Alternative to Polysorbates in Biopharmaceutical Formulation	—	How polysorbate failure modes affect mAb formulations and why rHSA stabilizes high-concentration biologics.
Blog	The “Cheap” Albumin Paradox: The Actuarial Cost of Serum Albumin in Biomanufacturing	CHO, T Lymphocyte	Genzyme Vesivirus 2117 case study and the economic case for recombinant raw materials.
Blog	Supply Chain Resilience: The Fragility and Finite Nature of Serum-Derived Raw Materials	—	Why supply chain volatility in serum-derived raw materials affects mAb manufacturing.
Blog	Safety and Contamination Risks: The Testing Burden and Persistent Threats	—	Adventitious agent risks in FBS-supplemented mAb production.
Blog	Variability and Failed Lots: The Hidden Quality Control Challenge of Serum & Serum-Derived Products	—	Lot-to-lot inconsistency in plasma HSA and impact on reproducibility.
Blog	Consistency Is the New Compliance	—	Regulatory framework for ancillary materials in biomanufacturing.
Blog	Why Do Some Biologics Cross the Finish Line—While Others Crash and Burn?	—	Why ~50% of BLA submissions stumble at CMC — Eli Lilly Liprotamase, Pfizer Zyvox, Chiron Fluvirin case studies.
Blog	How Regulatory Bodies Are Driving the Shift to Animal-Origin-Free Solutions in Cell Therapy and Vaccine Development	—	Regulatory drivers for AOF materials in biomanufacturing.